Alnylam Pharmaceuticals, Inc.
Alliance formed for intellectual property for RNAi therapeutics
Published in Healthcare Finance, Tax and Law Weekly, May 11th, 2005
Under the agreement, Alnylam will provide Benitec and its licensees an option to non-exclusively license Alnylam-controlled IP in the field of expressed RNAi: targeted gene silencing mediated by short interfering RNAs (siRNAs) generated from DNA constructs introduced into cells.
Upon Benitec's exercise of this option, Alnylam would receive license fees and be entitled to receive...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly
More Articles from Healthcare Finance, Tax and Law Weekly
- Adventrx Pharmaceuticals, Inc.
Pharmaceutical firm reports loss of $0.04 per share - Akzo Nobel
Pharmaceutical firm publishes full-year 2004 figures under IFRS rules - American Oriental Bioengineering, Inc.
Chinese pharmaceutical firm reports 53.2% increase in revenue - Andromed, Inc.
Diagnostics developer reports loss of $0.03 per share - Arrhythmia Research Technology, Inc.
Medical device maker declares cash dividend - Arrow International, Inc.
Medical device firm seeks extension to file quarterly report with SEC - More from this issue of Healthcare Finance, Tax and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
